Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.
Saved in:
| Title: | Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies. |
|---|---|
| Authors: | Ojala VK; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.; Turku Doctoral Programme of Molecular Medicine, Finland., Ahonen S; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland., Peltola S; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.; Turku Doctoral Programme of Molecular Medicine, Finland.; InFLAMES Research Flagship, University of Turku, Finland., Tuohisto-Kokko A; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland., Esparta O; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland., Suominen P; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland., Jokilammi A; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland., Farahani I; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.; Turku Doctoral Programme of Molecular Medicine, Finland.; InFLAMES Research Flagship, University of Turku, Finland., Chakroborty D; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.; Turku Doctoral Programme of Molecular Medicine, Finland., Dibus N; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland., Boettcher S; Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Switzerland., Airenne TT; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.; InFLAMES Research Flagship Center, Åbo Akademi University, Turku, Finland., Johnson MS; Structural Bioinformatics Laboratory, Biochemistry, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.; InFLAMES Research Flagship Center, Åbo Akademi University, Turku, Finland., Eli LD; Translational Medicine and Diagnostics, Puma Biotechnology Inc., Los Angeles, CA, USA., Elenius K; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.; InFLAMES Research Flagship, University of Turku, Finland.; Department of Oncology, Turku University Hospital, Finland., Kurppa KJ; Institute of Biomedicine, and MediCity Research Laboratory, University of Turku, Finland.; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland. |
| Source: | Molecular oncology [Mol Oncol] 2026 May; Vol. 20 (5), pp. 1323-1346. Date of Electronic Publication: 2025 Dec 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.70189 |
